Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth for nearly twice as long as a placebo, researchers from Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania announced as they reported on a randomized phase III trial at the ASCO Annual...
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan...